TAIPEI (Taiwan News) — Bora Pharmaceuticals and PharmaEssentia reported strong June revenue growth as global expansion and demand for pharmaceutical products boosted their businesses.
Bora Pharmaceuticals reported June revenue of NT$2.3 billion (US$71.4 million), up 39.22% year-on-year and a monthly record high, per CNA. First-half revenue totaled NT$9.89 billion, down 1.14% from a year earlier, but the company said it expects to return to growth in the second half.
Bora said June growth was driven by its US subsidiary Upsher-Smith Laboratories returning to growth after a product portfolio restructuring, as well as stable contract development and manufacturing organization (CDMO) operations in Taiwan and North America, per Liberty Times. The company said its flagship generic drug maintained market share, while specialty products grew.
Bora said its acquisition of a biologics CDMO facility in Rockville, Maryland, from MacroGenics for NT$3.93 billion will further strengthen its global manufacturing network. The facility, which has commercial-scale monoclonal antibody production orders, is expected to provide additional momentum for Bora’s biologics business.
The company said the Rockville facility will help diversify its revenue sources across small-molecule drugs, sterile injections, ophthalmic products, and biologics.
Meanwhile, PharmaEssentia reported June revenue of NT$2.33 billion, up 94.9% year-on-year and the second-highest monthly level on record, per Anue. First-half revenue reached NT$11.98 billion, up 74.6% year-on-year and a record high for the period, driven by continued global sales of its blood cancer drug Ropeg.
PharmaEssentia said it has applied for regulatory approval in multiple markets for Ropeg as a treatment for essential thrombocythemia, with the US FDA’s target action date set for Aug. 30. Reviews are also underway in Japan, China, and South Korea as the company seeks to expand the drug’s global market reach.
